107 related articles for article (PubMed ID: 2346867)
1. The use of small fraction numbers in high dose-rate gynaecological afterloading: some radiobiological considerations.
Dale RG
Br J Radiol; 1990 Apr; 63(748):290-4. PubMed ID: 2346867
[TBL] [Abstract][Full Text] [Related]
2. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix.
Leborgne F; Fowler JF; Leborgne JH; Zubizarreta E; Chappell R
Radiat Oncol Investig; 1997; 5(6):289-99. PubMed ID: 9436246
[TBL] [Abstract][Full Text] [Related]
3. [The radiobiology of gynecologic HDR and LDR afterloading technics].
Bauer M; Schulz-Wendtland R
Rontgenblatter; 1989 Jan; 42(1):54-6. PubMed ID: 2645638
[TBL] [Abstract][Full Text] [Related]
4. Analysis of factors affecting the therapeutic gain in high dose rate gynecological implants relative to low dose rate implants.
Sahoo N; Ling CC; Anderson LL
Med Phys; 1996 Mar; 23(3):419-25. PubMed ID: 8815385
[TBL] [Abstract][Full Text] [Related]
5. High dose rate gynecological applications--radiobiological considerations based on the alpha-beta model.
Ling CC; Sahoo N; Leibel S; Anderson LL
Radiother Oncol; 1992 Oct; 25(2):103-10. PubMed ID: 1438929
[TBL] [Abstract][Full Text] [Related]
6. [Gynecologic brachytherapy--from low-dose-rate to high-tech].
Herrmann T; Christen N; Alheit HD
Strahlenther Onkol; 1993 Mar; 169(3):141-51. PubMed ID: 8465248
[TBL] [Abstract][Full Text] [Related]
7. HDR versus LDR gynecological brachytherapy revisited.
Scalliet P; Gerbaulet A; Dubray B
Radiother Oncol; 1993 Aug; 28(2):118-26. PubMed ID: 8248552
[TBL] [Abstract][Full Text] [Related]
8. Fractionated high dose rate versus low dose rate regimens for intracavitary brachytherapy of the cervix. I. General considerations based on radiobiology.
Brenner DJ; Hall EJ
Br J Radiol; 1991 Feb; 64(758):133-41. PubMed ID: 2004204
[TBL] [Abstract][Full Text] [Related]
9. Determination of the appropriate fraction number and size of the HDR brachytherapy for cervical cancer.
Liu WS; Yen SH; Chang CH; Yang KM; Wu YP; Chen KY
Gynecol Oncol; 1996 Feb; 60(2):295-300. PubMed ID: 8631555
[TBL] [Abstract][Full Text] [Related]
10. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
11. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
Erickson B; Eifel P; Moughan J; Rownd J; Iarocci T; Owen J
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1083-92. PubMed ID: 16099599
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations.
Guerrero M; Li XA; Ma L; Linder J; Deyoung C; Erickson B
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):933-9. PubMed ID: 15936580
[TBL] [Abstract][Full Text] [Related]
13. Radiobiological equivalent of low/high dose rate brachytherapy and evaluation of tumor and normal responses to the dose.
Manimaran S
Radiat Med; 2007 Jun; 25(5):229-35. PubMed ID: 17581712
[TBL] [Abstract][Full Text] [Related]
14. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
[TBL] [Abstract][Full Text] [Related]
15. Calculation of integrated biological response in brachytherapy.
Dale RG; Coles IP; Deehan C; O'Donoghue JA
Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):633-42. PubMed ID: 9231690
[TBL] [Abstract][Full Text] [Related]
16. Biological effective dose evaluation in gynaecological brachytherapy: LDR and HDR treatments, dependence on radiobiological parameters, and treatment optimisation.
Bianchi C; Botta F; Conte L; Vanoli P; Cerizza L
Radiol Med; 2008 Oct; 113(7):1068-78. PubMed ID: 18618074
[TBL] [Abstract][Full Text] [Related]
17. Treatment planning for MRI assisted brachytherapy of gynecologic malignancies based on total dose constraints.
Lang S; Kirisits C; Dimopoulos J; Georg D; Pötter R
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):619-27. PubMed ID: 17869676
[TBL] [Abstract][Full Text] [Related]
18. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma.
Lertsanguansinchai P; Lertbutsayanukul C; Shotelersuk K; Khorprasert C; Rojpornpradit P; Chottetanaprasith T; Srisuthep A; Suriyapee S; Jumpangern C; Tresukosol D; Charoonsantikul C
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1424-31. PubMed ID: 15275728
[TBL] [Abstract][Full Text] [Related]
20. High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer.
Kucera H; Pötter R; Knocke TH; Baldass M; Kucera E
Wien Klin Wochenschr; 2001 Jan; 113(1-2):58-62. PubMed ID: 11233470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
